GlassScriptPhysician profile
Sharon L Smith
NPI 1891068938
$1,851.27
in general payments reported to CMS, 2019-2025
27 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $697 · 2022: $255 · 2023: $454 · 2024: $207 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $474.49 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.73 | 2021-2025 | Relistor |
| Averitas Pharma INC. | $174.56 | 2023-2025 | Qutenza |
| Biodelivery Sciences International, INC. | $116.11 | 2021 | |
| Merck Sharp & Dohme LLC | $94.00 | 2022-2023 | Belsomra |
| Arbor Pharmaceuticals, INC. | $86.96 | 2021 | |
| Grt US Holding, INC. | $74.08 | 2021 | |
| Scilex Pharmaceuticals INC. | $65.37 | 2021-2023 | Ztlido |
| Medtronic, INC. | $64.40 | 2021-2022 | |
| Ucb, INC. | $41.68 | 2025 | Bimzelx |
| Baudax Bio INC. | $36.72 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $31.52 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $30.41 | 2021 | |
| Valinor Pharma, LLC | $28.76 | 2025 | Movantik |
| Lilly USA, LLC | $27.71 | 2021-2023 | Reyvow, Emgality |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.51 | 2021-2023 | |
| Abbott Laboratories | $25.96 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $24.84 | 2025 | Zilretta, Iovera |
| Amgen INC. | $23.43 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.61 | 2024 | |
| Bioventus LLC | $19.97 | 2021 | |
| Allergan, INC. | $19.30 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.16 | 2024 | Horizant |
| Ibsa Pharma INC. | $13.53 | 2021 | |
| Baxter Healthcare | $12.36 | 2022 | |
| Amneal Pharmaceuticals LLC | $12.25 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.